Cannabis Compound Targets Breast Cancer Estrogen Signals

Could a compound found in cannabis help an established breast cancer medicine work more effectively? Answering that question could open a useful path for drug development, particularly if researchers can identify exactly which molecule produces the effect and which tumors respond.

A new study published in Biomedicine & Pharmacotherapy investigates a cannabinoid called 373.15b in laboratory experiments and mice.¹ Researchers found that it reduced estrogen receptor activity and inhibited tumor growth, with encouraging results when combined with tamoxifen.

The findings support further investigation of a specific experimental compound. Their broader significance lies in how the researchers reached it: moving from complex cannabis extracts toward a defined molecule, a biological explanation, and a treatment combination that can be tested more precisely.

Why Estrogen Matters in Breast Cancer Research

Breast cancer includes several diseases with different biological characteristics. In estrogen receptor-positive breast cancer, tumor cells carry proteins that respond to estrogen and help activate growth-related instructions. Estrogen receptor alpha, abbreviated ERα, is one important part of that machinery.

Think of the receptor as a receiver for a growth signal. Tamoxifen interferes with that signal in breast tissue. It belongs to a group of medicines called selective estrogen receptor modulators, or SERMs.

Endocrine treatment can continue for years, making tolerability important alongside effectiveness. The researchers therefore explored whether a cannabis-derived compound could make cancer cells more sensitive to existing treatment. Their longer-term hypothesis is that a successful combination might eventually permit lower doses, although this study did not establish that benefit in patients.

This question differs from whether cannabis helps someone manage symptoms. MyCannabis’s recent coverage of cannabis in palliative care examines comfort and pain relief. Here, the experimental target was tumor biology itself. Both research directions matter, but success in one does not establish success in the other.

How Researchers Identified Cannabinoid 373.15b

The team began with 29 chemically distinct cannabis extracts and tested their effects on breast cancer cells. One extract, CANN14, stood out for its ability to increase the cell-killing effect of tamoxifen under the screening conditions.

Researchers then separated that extract into smaller chemical fractions. This process progressively narrowed the search, allowing them to identify 373.15b as an active component. They characterized its unusual chemical structure and also tested a synthetic version.

That synthetic step strengthens the investigation. When a chemically defined molecule reproduces an effect, researchers gain confidence about what deserves further testing. It also creates a route toward experiments using consistent material rather than depending entirely on variable plant extracts.

The work combined experiments in estrogen receptor-positive breast cancer cell lines with an animal model. Female mice received estrogen supplementation and implanted human breast cancer cells, allowing researchers to observe tumor growth during treatment.

Groups generally contained five or six mice. Treatments were delivered by injection into the abdominal cavity. These conditions provide useful experimental control, but they do not reproduce someone taking a cannabis oil or capsule at home.

What the Breast Cancer Experiments Found

The compound reduced ERα gene expression, protein levels, and activity. In practical terms, the cells had less of the receptor machinery associated with estrogen-driven growth, and some of the instructions controlled by that machinery became less active.

The researchers also observed changes involving RASSF1A, a protein associated with tumor suppression, and the Hippo signaling pathway, which helps regulate cell growth. These findings suggest a possible explanation for the receptor changes. However, the compound’s direct molecular target remains unidentified, and the proposed sequence still requires stronger causal testing.

In mice, both CANN14 and synthetic 373.15b inhibited tumor progression. Combination treatment produced encouraging effects, although the extract and isolated-compound experiments should be read separately.

For example, in the CANN14 experiment, tumors in the combination group were approximately one-quarter the volume of those in the vehicle control group after about four weeks. That comparison describes smaller tumors relative to untreated controls. It does not mean tumors shrank by 75% from their starting size.

The following findings and constraints come directly from the paper:

Why a Defined Molecule Changes the Research Question

One of the most useful lessons is that “cannabis” is too broad a description for this potential treatment. Only one extract emerged from the initial screen as effective in combination with tamoxifen. The chemical differences between extracts were therefore central to the discovery.

For future research, this shifts the question toward composition: which molecule, at which exposure, produces which response? Those details make findings easier to reproduce and help explain why two cannabis preparations might behave differently.

The study also illustrates how plant research and pharmaceutical development can connect. Cannabis supplied the starting material, while chemical isolation and synthesis helped turn an observation into a more testable candidate.

The project already has institutional support. An August 2026 Technion announcement described cancer research funding involving 373.15b. That support provides context for the research program, although funding itself does not validate a treatment.

Related CBD Findings Add Context, Not Interchangeability

A separate study published in May 2026 investigated CBD and tamoxifen in preclinical breast cancer models. It reported enhanced treatment effects associated with changes in another signaling system, the cAMP/CREB pathway.

Together, these experiments suggest that cannabinoid research may uncover several ways to influence estrogen-related cancer biology. They do not establish that CBD and 373.15b are interchangeable, or that a commercial product can reproduce either experiment. Comparing the compounds under matched conditions would be more informative than grouping their results under a single cannabis claim.

What Would Make the Findings Useful for Patients?

A promising tumor result is one part of a future medicine’s evaluation. Researchers also need to establish whether an effective amount can reach the tumor, how long it remains active, and what happens elsewhere in the body.

Delivery deserves particular attention. MyCannabis’s coverage of CBD liposomes for radiation-related lung injury explores another experimental setting where formulation is part of the treatment question. For 373.15b, absorption and bioavailability remain open issues. An injected mouse dose cannot simply be converted into a consumer serving.

The most useful next steps include:

• Confirming the findings in additional tumor models and independent laboratories.
• Measuring exposure, metabolism, and effects on healthy tissues.
• Testing whether lower-dose combinations preserve tumor control while reducing overall toxicity.

The final point is especially important. Adding a compound could improve antitumor activity while also adding unwanted effects. Demonstrating a better treatment requires measuring both sides of that balance. Lower tamoxifen requirements would become meaningful only if the complete regimen proved effective and better tolerated.

The authors acknowledge that estrogen receptors also serve normal tissues, making endocrine effects outside tumors relevant. The paper also discloses David Meiri’s board relationship with Cannasoul Analytics and a pending related patent. These disclosures reinforce the value of independent replication.

The Next Question for Cannabinoid Breast Cancer Research

The strongest contribution of this study is a clearer experimental direction. Researchers have a defined compound, measurable changes in estrogen signaling, and animal findings that justify further work.

For readers, the distinction is straightforward: this is a drug-development lead, not evidence for replacing endocrine treatment or adding retail cannabis to improve cancer control. Decisions involving existing medicines belong with the treating oncology team.

The next decisive experiment should ask whether 373.15b can deliver a reproducible therapeutic advantage at exposures that are tolerable throughout the body. If it can, the discovery would move beyond an interesting plant compound toward a more useful possibility: a carefully designed partner for established breast cancer treatment.

References:

¹ Cohen, V., Besser, E., Shotan, S. R., Procaccia, S., Halle-Bikovski, A., Litvinsky, S. S., Truman, M., Harel, M., Thaler, S., & Meiri, D. (2026). Estrogen receptor modulation by a newly-identified cannabinoid in a preclinical model of breast cancer. Biomedicine & Pharmacotherapy, 204, 119942. https://doi.org/10.1016/j.biopha.2026.119942